Lantheus Receives FDA Tentative Approval for Lutetium Lu 177 Dotatate (PNT2003), Radioequivalent to LUTATHERA®

Rhea-AI Summary

Lantheus (NASDAQ: LNTH) received FDA tentative approval for its ANDA of Lutetium Lu 177 Dotatate (PNT2003), a radioequivalent to LUTATHERA®, on March 2, 2026. The tentative approval confirms the ANDA meets statutory requirements but full approval awaits expiration of a 30-month stay in June 2026.

The company licensed exclusive worldwide rights to PNT2003 from POINT Biopharma in December 2022; POINT was later acquired by Eli Lilly. Lantheus says it expects to seek final approval and make PNT2003 available to patients pending regulatory clearance.

Positive

• FDA tentative approval received for PNT2003 ANDA
• First radioequivalent to LUTATHERA to receive tentative approval
• Exclusive worldwide license to PNT2003 from POINT (Dec 2022)

Negative

• Full approval delayed pending 30-month stay expiration in June 2026
• Regulatory timing risk tied to Hatch-Waxman litigation stay

Key Figures

30-month stay: 30-month stay Stay expiration: June 2026 Licensing date: December 2022 +1 more

4 metrics

30-month stay 30-month stay Duration of stay delaying full ANDA approval to June 2026

Stay expiration June 2026 Expected expiration timing of 30-month stay on PNT2003 ANDA

Licensing date December 2022 Date Lantheus licensed PNT2003 rights from POINT Biopharma

Acquisition date December 2023 Date POINT Biopharma was acquired by Eli Lilly

Market Reality Check

Price: $74.91 Vol: Volume 1,349,924 is 1.49x...

normal vol

$74.91 Last Close

Volume Volume 1,349,924 is 1.49x the 20-day average of 907,464, indicating elevated interest ahead of this news. normal

Technical Shares at $74.91 are trading above the 200-day MA of $64.97 but sit 32.69% below the 52-week high of $111.29.

Peers on Argus

LNTH slipped 0.69% with key peers also down: ALKS -0.82%, AMRX -2.95%, INDV -1.3...

LNTH slipped 0.69% with key peers also down: ALKS -0.82%, AMRX -2.95%, INDV -1.30%, PBH -0.42%, HCM -0.35%. The pre-news drift aligns with broader weakness in specialty/generic drug names rather than LNTH-specific trading.

Historical Context

5 past events · Latest: Feb 26 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 26	Earnings and guidance	Positive	-0.4%	Reported strong 2025 revenue and EPS with 2026 guidance and portfolio updates.
Feb 24	Investor conferences	Neutral	+0.3%	Announced CEO presentations at two March 2026 healthcare investor conferences.
Feb 12	Earnings call scheduling	Neutral	+2.1%	Set date and time for Q4 and full-year 2025 earnings call and webcast.
Jan 02	Business divestiture	Positive	+1.1%	Closed sale of SPECT business to sharpen focus on PET radiodiagnostics.
Nov 24	Clinical data presentation	Neutral	+1.2%	Planned CTAD 2025 presentation of new florbetaben F 18 Alzheimer’s imaging data.

Pattern Detected

Recent news, including solid earnings and strategic portfolio moves, has more often seen modest positive reactions, with one notable divergence on the latest earnings release.

Recent Company History

Over the last few months, Lantheus has emphasized a shift toward radiopharmaceutical oncology and precision diagnostics, highlighted by divesting its SPECT business and integrating acquisitions like Life Molecular Imaging and Evergreen. Earnings on Feb 26, 2026 showed strong FY2025 revenue of $1.54 billion and adjusted EPS of $6.08, yet the stock dipped slightly. Today’s PNT2003 tentative approval fits the broader strategy, adding a key GEP-NETs asset alongside existing PET radiodiagnostics.

Market Pulse Summary

This announcement underscores Lantheus’ radiopharmaceutical strategy, with FDA tentative approval of...

Analysis

This announcement underscores Lantheus’ radiopharmaceutical strategy, with FDA tentative approval of PNT2003, a radioequivalent to LUTATHERA for GEP-NETs, adding a key therapeutic asset. Full ANDA approval remains contingent on a 30‑month stay expiring in June 2026 tied to Hatch‑Waxman patent litigation, a risk already flagged in recent SEC filings. Investors may watch for updates on that litigation, final approval timing, and how PNT2003 complements the company’s existing PET radiodiagnostics and broader oncology portfolio.

Key Terms

abbreviated new drug application, radioequivalent, gastroenteropancreatic neuroendocrine tumors, radiopharmaceutical, +2 more

6 terms

abbreviated new drug application regulatory

"received U.S. Food and Drug Administration (FDA) tentative approval for the Abbreviated New Drug Application (ANDA)"

An abbreviated new drug application is a regulatory submission used to gain approval to market a generic version of an already approved prescription medicine by showing it is equivalent in effect and safety to the original product, without repeating full clinical trials. For investors, an approval signals a lower-cost competitor entering the market that can quickly capture sales from the branded drug, similar to a generic knock‑off replacing a name‑brand item on store shelves.

radioequivalent medical

"PNT2003, a radioequivalent1 version of LUTATHERA"

Radioequivalent describes the mass or amount of a chemical compound that corresponds to a given level of radioactivity in a radiopharmaceutical, calculated from the product’s specific activity. For investors, it matters because the radioequivalent affects dosing, manufacturing yield and regulatory safety assessments—think of it like knowing how much salt is in a salty solution based on how salty it tastes: the radioequivalent tells you how much non‑radioactive substance accompanies the radioactive signal.

gastroenteropancreatic neuroendocrine tumors medical

"for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs)"

Gastroenteropancreatic neuroendocrine tumors are cancers that start in hormone-making cells scattered through the digestive tract and pancreas; these cells act like tiny thermostats that release hormones and can form tumors that grow slowly or aggressively. Investors care because these tumors create specific medical needs—drugs, tests and procedures—that can drive product sales, regulatory approvals, clinical trial milestones and partnerships, so progress or setbacks in treatment development can directly affect company value.

radiopharmaceutical medical

"leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease"

A radiopharmaceutical is a special type of medicine that contains a small amount of radioactive material, used primarily for medical imaging or treatment. It can be thought of as a tiny, targeted signal that helps doctors see inside the body or deliver therapy directly to affected areas. For investors, understanding radiopharmaceuticals is important because they represent a growing field within healthcare, driven by advancements in diagnostics and personalized treatments.

hatch-waxman regulatory

"30-month stay in June 2026, triggered in connection with a Hatch-Waxman patent litigation"

Hatch‑Waxman is a U.S. law that creates a fast-track pathway for generic drug makers to prove a copy of an approved medicine is the same, while also letting original drug makers restore some patent life and win short-term exclusivity. Think of it as a legal balancing act that decides when cheaper copies can enter the market and when brand-name drugs keep protection—information that directly affects future sales, competition, and company valuations.

patent litigation regulatory

"30-month stay in June 2026, triggered in connection with a Hatch-Waxman patent litigation"

A court fight over who has the legal right to make, use or sell a particular invention or product design. For investors it matters because the outcome can block sales, force royalty payments or open the door to wider market access, much like a disputed property line can prevent someone from building or selling on a plot of land and change the expected value of an investment.

AI-generated analysis. Not financial advice.

BEDFORD, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that it has received U.S. Food and Drug Administration (FDA) tentative approval for the Abbreviated New Drug Application (ANDA) for Lutetium Lu 177 Dotatate (PNT2003), a radioequivalent¹ version of LUTATHERA^® (lutetium Lu 177 dotatate). LUTATHERA^® is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors. 

“As the first radioequivalent to LUTATHERA to receive FDA tentative approval, PNT2003 marks an important step forward in Lantheus’ work to advance treatment options for patients with GEP-NETs. This milestone comes at a time when advances in imaging and evolving clinical guidelines are enabling the identification of more patients who stand to benefit from targeted radiopharmaceutical therapies. As the leading radiopharmaceutical-focused company, we remain committed to meeting this growing demand and look forward to making PNT2003 available to patients pending final FDA approval,” said Mary Anne Heino, Chief Executive Officer of Lantheus.

The FDA tentative approval indicates that the FDA has completed its review of the ANDA and that it meets the requirements for approval under the Federal Food, Drug and Cosmetics Act. Full approval of the ANDA is subject to the expiration of the 30-month stay in June 2026, triggered in connection with a Hatch-Waxman patent litigation.

Lantheus licensed exclusive worldwide rights (excluding certain territories) to PNT2003 from POINT Biopharma Global, Inc. in December 2022. To read the press release announcing that licensing transaction, please click here. POINT was acquired by Eli Lilly and Company in December 2023.

About GEP-NETs
Neuroendocrine tumors (NETs) are rare, often slow-growing cancers that can develop throughout the body. A subset known as gastroenteropancreatic NETs (GEP-NETs) affects the digestive system and pancreas and may be functional or non-functional depending on hormone activity.² Over the last few decades, the incidence of GEP-NETs has increased significantly, with the prevalence in the U.S. estimated to be approximately 200,000 patients.³ Because GEP-NETs often grow slowly and cause non-specific symptoms, up to 50% are initially misdiagnosed, with patients waiting an average of 4.3 years from symptom onset to diagnosis.^4,5

About Lantheus
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Sweden, Switzerland and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for more than 70 years. For more information, visit www.lantheus.com. 

Safe Harbor for Forward-Looking and Cautionary Statements 
This press release contains “forward-looking statements” that are subject to risks and uncertainties. Forward-looking statements include, but are not limited to, statements relating to the potential FDA full approval of PNT2003 and statements regarding Lantheus’ expectations, hopes, beliefs, intentions or strategies regarding the future. Forward-looking statements may be identified by their use of terms such as “forward,” “look” and other similar terms. Such forward-looking statements are based upon current plans, estimates and expectations that are subject to risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements.

¹The term radioequivalent is used to describe a radiopharmaceutical whose mechanism of action is determined to be equivalent to that of the reference product approved by the FDA, or a similar regulator outside of the US.
²Neuroendocrine Tumors. Cleveland Clinic. Published June 26, 2024. Accessed May 22, 2025. https://my.clevelandclinic.org/health/diseases/22006-neuroendocrine-tumors-net
³Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017 Oct 1;3(10):1335-1342. doi: 10.1001/jamaoncol.2017.0589. PMID: 28448665; PMCID: PMC5824320. 
⁴Kolarova T, et.al. P-136 Survey of challenges in access to diagnostics and treatment for neuroendocrine tumor patients (SCAN): Early diagnosis and treatment availability. Annals of Oncology, Volume 31, S134.
⁵Raphael MJ, Chan DL, Law C, Singh S. Principles of diagnosis and management of neuroendocrine tumours. CMAJ. 2017 Mar 13;189(10):E398-E404. doi: 10.1503/cmaj.160771. PMID: 28385820; PMCID: PMC5359105.

LUTATHERA^® is a registered trademark of Novartis AG and/or its affiliates.

Contacts:
Mark Kinarney
Vice President, Investor Relations 
978-671-8842
ir@lantheus.com  

Melissa Downs
Executive Director, External Communications
646-975-2533 
media@lantheus.com  

FAQ

What does the FDA tentative approval for PNT2003 announced March 2, 2026 mean for LNTH?

It means the ANDA met FDA review requirements but is not final approval. According to the company, tentative approval confirms regulatory review completion; final approval depends on the 30-month stay expiring in June 2026 tied to Hatch-Waxman litigation.

When could Lantheus (LNTH) receive full FDA approval for PNT2003?

Final approval could occur after the 30-month stay expires in June 2026. According to the company, full ANDA approval is contingent on that stay triggered by Hatch-Waxman patent litigation and subsequent regulatory clearance timing.

How does PNT2003 relate to LUTATHERA and LNTH's product strategy?

PNT2003 is a radioequivalent to LUTATHERA intended for the same GEP-NET indication. According to the company, offering a radioequivalent aligns with Lantheus' radiopharmaceutical focus and could expand patient access pending final approval.

What licensing deal did Lantheus use to acquire PNT2003 rights (LNTH)?

Lantheus licensed exclusive worldwide rights to PNT2003 from POINT in December 2022. According to the company, that licensing transaction granted rights (excluding certain territories) to develop and seek approval of PNT2003.

Does the March 2, 2026 announcement affect patient access to GEP-NET treatments now?

Tentative approval itself does not change current patient access until full approval is granted. According to the company, Lantheus plans to make PNT2003 available to patients pending final FDA approval after the stay ends.

What regulatory risk should investors in LNTH consider after the tentative approval?

Investors should note timing risk from the 30-month stay tied to patent litigation that delays final approval. According to the company, the ANDA's full approval is subject to that stay expiring in June 2026.